Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Aug;40(8):1759–1767. doi: 10.1128/aac.40.8.1759

Susceptibility testing of Mycobacterium avium complex isolates.

L Heifets 1
PMCID: PMC163414  PMID: 8843278

Full Text

The Full Text of this article is available as a PDF (225.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahn C. H., Ahn S. S., Anderson R. A., Murphy D. T., Mammo A. A four-drug regimen for initial treatment of cavitary disease caused by Mycobacterium avium complex. Am Rev Respir Dis. 1986 Sep;134(3):438–441. doi: 10.1164/arrd.1986.134.3.438. [DOI] [PubMed] [Google Scholar]
  2. Ahn C. H., McLarty J. W., Ahn S. S., Ahn S. I., Hurst G. A. Diagnostic criteria for pulmonary disease caused by Mycobacterium kansasii and Mycobacterium intracellulare. Am Rev Respir Dis. 1982 Apr;125(4):388–391. doi: 10.1164/arrd.1982.125.4.388. [DOI] [PubMed] [Google Scholar]
  3. Baron E. J., Young L. S. Amikacin, ethambutol, and rifampin for treatment of disseminated Mycobacterium avium-intracellulare infections in patients with acquired immune deficiency syndrome. Diagn Microbiol Infect Dis. 1986 Sep;5(3):215–220. doi: 10.1016/0732-8893(86)90004-0. [DOI] [PubMed] [Google Scholar]
  4. Bates J. H. A study of pulmonary disease associated with mycobacteria other than Mycobacterium tuberculosis: clinical characteristics. XX. A report of the Veterans Administration-armed forces cooperative study on the chemotherapy of tuberculosis. Am Rev Respir Dis. 1967 Dec;96(6):1151–1157. doi: 10.1164/arrd.1967.96.6.1151. [DOI] [PubMed] [Google Scholar]
  5. Benson C. A., Kessler H. A., Pottage J. C., Jr, Trenholme G. M. Successful treatment of acquired immunodeficiency syndrome-related Mycobacterium avium complex disease with a multiple drug regimen including amikacin. Arch Intern Med. 1991 Mar;151(3):582–585. [PubMed] [Google Scholar]
  6. CORPE R. F. CLINICAL ASPECTS, MEDICAL AND SURGICAL, IN THE MANAGEMENT OF BATTEY-TYPE PULMONARY DISEASE. Dis Chest. 1964 Apr;45:380–382. doi: 10.1378/chest.45.4.380. [DOI] [PubMed] [Google Scholar]
  7. CROW H. E., KING C. T., SMITH C. E., CORPE R. F., STERGUS I. A limited clinical, pathologic, and epidemiologic study of patients with pulmonary lesions associated with atypical acid-fast bacilli in the sputum. Am Rev Tuberc. 1957 Feb;75(2):199–222. doi: 10.1164/artpd.1957.75.2.199. [DOI] [PubMed] [Google Scholar]
  8. Chaisson R. E., Benson C. A., Dube M. P., Heifets L. B., Korvick J. A., Elkin S., Smith T., Craft J. C., Sattler F. R. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med. 1994 Dec 15;121(12):905–911. doi: 10.7326/0003-4819-121-12-199412150-00001. [DOI] [PubMed] [Google Scholar]
  9. Chaisson R. E., Moore R. D., Richman D. D., Keruly J., Creagh T. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. Am Rev Respir Dis. 1992 Aug;146(2):285–289. doi: 10.1164/ajrccm/146.2.285. [DOI] [PubMed] [Google Scholar]
  10. Chiu J., Nussbaum J., Bozzette S., Tilles J. G., Young L. S., Leedom J., Heseltine P. N., McCutchan J. A. Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group. Ann Intern Med. 1990 Sep 1;113(5):358–361. doi: 10.7326/0003-4819-113-5-358. [DOI] [PubMed] [Google Scholar]
  11. Christensen E. E., Dietz G. W., Ahn C. H., Chapman J. S., Murry R. C., Anderson J., Hurst G. A. Pulmonary manifestations of Mycobacterium intracellularis. AJR Am J Roentgenol. 1979 Jul;133(1):59–66. doi: 10.2214/ajr.133.1.59. [DOI] [PubMed] [Google Scholar]
  12. Cooksey R. C., Crawford J. T., Jacobs W. R., Jr, Shinnick T. M. A rapid method for screening antimicrobial agents for activities against a strain of Mycobacterium tuberculosis expressing firefly luciferase. Antimicrob Agents Chemother. 1993 Jun;37(6):1348–1352. doi: 10.1128/aac.37.6.1348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cynamon M. H. Comparative in vitro activities of MDL 473, rifampin, and ansamycin against Mycobacterium intracellulare. Antimicrob Agents Chemother. 1985 Sep;28(3):440–441. doi: 10.1128/aac.28.3.440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Cynamon M. H., Palmer G. S., Sorg T. B. Comparative in vitro activities of ampicillin, BMY 28142, and imipenem against Mycobacterium avium complex. Diagn Microbiol Infect Dis. 1987 Feb;6(2):151–155. doi: 10.1016/0732-8893(87)90100-3. [DOI] [PubMed] [Google Scholar]
  15. Dautzenberg B. Clinical trials in Mycobacterium avium therapy: lessons to take home. Res Microbiol. 1994 Mar-Apr;145(3):197–206. doi: 10.1016/0923-2508(94)90018-3. [DOI] [PubMed] [Google Scholar]
  16. Dautzenberg B., Saint Marc T., Meyohas M. C., Eliaszewitch M., Haniez F., Rogues A. M., De Wit S., Cotte L., Chauvin J. P., Grosset J. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1993 Feb 8;153(3):368–372. [PubMed] [Google Scholar]
  17. Dautzenberg B., Truffot C., Legris S., Meyohas M. C., Berlie H. C., Mercat A., Chevret S., Grosset J. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):564–569. doi: 10.1164/ajrccm/144.3_Pt_1.564. [DOI] [PubMed] [Google Scholar]
  18. Davidson P. T., Khanijo V., Goble M., Moulding T. S. Treatment of disease due to Mycobacterium intracellulare. Rev Infect Dis. 1981 Sep-Oct;3(5):1052–1059. doi: 10.1093/clinids/3.5.1052. [DOI] [PubMed] [Google Scholar]
  19. Dutt A. K., Stead W. W. Long-term results of medical treatment in Mycobacterium intracellulare infection. Am J Med. 1979 Sep;67(3):449–453. doi: 10.1016/0002-9343(79)90792-7. [DOI] [PubMed] [Google Scholar]
  20. Falkinham J. O., 3rd, Parker B. C., Gruft H. Epidemiology of infection by nontuberculous mycobacteria. I. Geographic distribution in the eastern United States. Am Rev Respir Dis. 1980 Jun;121(6):931–937. doi: 10.1164/arrd.1980.121.6.931. [DOI] [PubMed] [Google Scholar]
  21. Fenlon C. H., Cynamon M. H. Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare. Antimicrob Agents Chemother. 1986 Mar;29(3):386–388. doi: 10.1128/aac.29.3.386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Fischer D. A., Lester W., Schaefer W. B. Infections with atypical mycobacteria. Five years' experience at the National Jewish Hospital. Am Rev Respir Dis. 1968 Jul;98(1):29–34. doi: 10.1164/arrd.1968.98.1.29. [DOI] [PubMed] [Google Scholar]
  23. Good R. C. From the Center for Disease Control. Isolation of nontuberculous mycobacteria in the United States, 1979. J Infect Dis. 1980 Nov;142(5):779–783. doi: 10.1093/infdis/142.5.779. [DOI] [PubMed] [Google Scholar]
  24. Good R. C. Opportunistic pathogens in the genus Mycobacterium. Annu Rev Microbiol. 1985;39:347–369. doi: 10.1146/annurev.mi.39.100185.002023. [DOI] [PubMed] [Google Scholar]
  25. Good R. C., Snider D. E., Jr Isolation of nontuberculous mycobacteria in the United States, 1980. J Infect Dis. 1982 Dec;146(6):829–833. doi: 10.1093/infdis/146.6.829. [DOI] [PubMed] [Google Scholar]
  26. Gordon S. M., Horsburgh C. R., Jr, Peloquin C. A., Havlik J. A., Jr, Metchock B., Heifets L., McGowan J. E., Jr, Thompson S. E., 3rd Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease. J Infect Dis. 1993 Dec;168(6):1559–1562. doi: 10.1093/infdis/168.6.1559. [DOI] [PubMed] [Google Scholar]
  27. Grange J., Collins C., Yates M. Bacteriological survey of tuberculous lymphadenitis in South-east England: 1973-80. J Epidemiol Community Health. 1982 Sep;36(3):157–161. doi: 10.1136/jech.36.3.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Greene J. B., Sidhu G. S., Lewin S., Levine J. F., Masur H., Simberkoff M. S., Nicholas P., Good R. C., Zolla-Pazner S. B., Pollock A. A. Mycobacterium avium-intracellulare: a cause of disseminated life-threatening infection in homosexuals and drug abusers. Ann Intern Med. 1982 Oct;97(4):539–546. doi: 10.7326/0003-4819-97-4-539. [DOI] [PubMed] [Google Scholar]
  29. Gruft H., Falkinham J. O., 3rd, Parker B. C. Recent experience in the epidemiology of disease caused by atypical mycobacteria. Rev Infect Dis. 1981 Sep-Oct;3(5):990–996. doi: 10.1093/clinids/3.5.990. [DOI] [PubMed] [Google Scholar]
  30. Hansen S. L., Swomley P., Drusano G. Effect of carbon dioxide and pH on susceptibility of Bacteroides fragilis group to erythromycin. Antimicrob Agents Chemother. 1981 Feb;19(2):335–336. doi: 10.1128/aac.19.2.335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Hawkins C. C., Gold J. W., Whimbey E., Kiehn T. E., Brannon P., Cammarata R., Brown A. E., Armstrong D. Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1986 Aug;105(2):184–188. doi: 10.7326/0003-4819-105-2-184. [DOI] [PubMed] [Google Scholar]
  32. Heifets L. B., Iseman M. D. Choice of antimicrobial agents for M. avium disease based on quantitative tests of drug susceptibility. N Engl J Med. 1990 Aug 9;323(6):419–420. doi: 10.1056/NEJM199008093230615. [DOI] [PubMed] [Google Scholar]
  33. Heifets L. B., Iseman M. D. Individualized therapy versus standard regimens in the treatment of Mycobacterium avium infections. Am Rev Respir Dis. 1991 Jul;144(1):1–2. doi: 10.1164/ajrccm/144.1.1. [DOI] [PubMed] [Google Scholar]
  34. Heifets L. B., Iseman M. D., Lindholm-Levy P. J. Ethambutol MICs and MBCs for Mycobacterium avium complex and Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1986 Dec;30(6):927–932. doi: 10.1128/aac.30.6.927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Heifets L. B., Lindholm-Levy P. J. Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tubercle. 1987 Dec;68(4):267–276. doi: 10.1016/0041-3879(87)90067-5. [DOI] [PubMed] [Google Scholar]
  36. Heifets L. B., Lindholm-Levy P. J., Comstock R. D. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):856–858. doi: 10.1164/ajrccm/145.4_Pt_1.856. [DOI] [PubMed] [Google Scholar]
  37. Heifets L. B., Lindholm-Levy P. J., Flory M. A. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am Rev Respir Dis. 1990 Mar;141(3):626–630. doi: 10.1164/ajrccm/141.3.626. [DOI] [PubMed] [Google Scholar]
  38. Heifets L. B. Quantitative cultures and drug susceptibility testing of Mycobacterium avium clinical isolates before and during the antimicrobial therapy. Res Microbiol. 1994 Mar-Apr;145(3):188–196. doi: 10.1016/0923-2508(94)90017-5. [DOI] [PubMed] [Google Scholar]
  39. Heifets L., Lindholm-Levy P. Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis. Antimicrob Agents Chemother. 1989 Aug;33(8):1298–1301. doi: 10.1128/aac.33.8.1298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Heifets L. MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs. Antimicrob Agents Chemother. 1988 Aug;32(8):1131–1136. doi: 10.1128/aac.32.8.1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Heifets L., Mor N., Vanderkolk J. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother. 1993 Nov;37(11):2364–2370. doi: 10.1128/aac.37.11.2364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Heifets L. Qualitative and quantitative drug-susceptibility tests in mycobacteriology. Am Rev Respir Dis. 1988 May;137(5):1217–1222. doi: 10.1164/ajrccm/137.5.1217. [DOI] [PubMed] [Google Scholar]
  43. Hoover D. R., Saah A. J., Bacellar H., Phair J., Detels R., Anderson R., Kaslow R. A. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N Engl J Med. 1993 Dec 23;329(26):1922–1926. doi: 10.1056/NEJM199312233292604. [DOI] [PubMed] [Google Scholar]
  44. Hopewell P., Cynamon M., Starke J., Iseman M., O'Brien R. Evaluation of new anti-infective drugs for the treatment and prevention of infections caused by the Mycobacterium avium complex. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992 Nov;15 (Suppl 1):S296–S306. doi: 10.1093/clind/15.supplement_1.s296. [DOI] [PubMed] [Google Scholar]
  45. Horsburgh C. R., Jr, Chin D. P., Yajko D. M., Hopewell P. C., Nassos P. S., Elkin E. P., Hadley W. K., Stone E. N., Simon E. M., Gonzalez P. Environmental risk factors for acquisition of Mycobacterium avium complex in persons with human immunodeficiency virus infection. J Infect Dis. 1994 Aug;170(2):362–367. doi: 10.1093/infdis/170.2.362. [DOI] [PubMed] [Google Scholar]
  46. Horsburgh C. R., Jr, Havlik J. A., Ellis D. A., Kennedy E., Fann S. A., Dubois R. E., Thompson S. E. Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):557–559. doi: 10.1164/ajrccm/144.3_Pt_1.557. [DOI] [PubMed] [Google Scholar]
  47. Horsburgh C. R., Jr, Mason U. G., 3rd, Heifets L. B., Southwick K., Labrecque J., Iseman M. D. Response to therapy of pulmonary Mycobacterium avium-intracellulare infection correlates with results of in vitro susceptibility testing. Am Rev Respir Dis. 1987 Feb;135(2):418–421. doi: 10.1164/arrd.1987.135.2.418. [DOI] [PubMed] [Google Scholar]
  48. Horsburgh C. R., Jr, Metchock B., Gordon S. M., Havlik J. A., Jr, McGowan J. E., Jr, Thompson S. E., 3rd Predictors of survival in patients with AIDS and disseminated Mycobacterium avium complex disease. J Infect Dis. 1994 Sep;170(3):573–577. doi: 10.1093/infdis/170.3.573. [DOI] [PubMed] [Google Scholar]
  49. Horsburgh C. R., Jr Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med. 1991 May 9;324(19):1332–1338. doi: 10.1056/NEJM199105093241906. [DOI] [PubMed] [Google Scholar]
  50. Horsburgh C. R., Jr, Selik R. M. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis. 1989 Jan;139(1):4–7. doi: 10.1164/ajrccm/139.1.4. [DOI] [PubMed] [Google Scholar]
  51. Hoy J., Mijch A., Sandland M., Grayson L., Lucas R., Dwyer B. Quadruple-drug therapy for Mycobacterium avium-intracellulare bacteremia in AIDS patients. J Infect Dis. 1990 Apr;161(4):801–805. doi: 10.1093/infdis/161.4.801. [DOI] [PubMed] [Google Scholar]
  52. Hunter A. M., Campbell I. A., Jenkins P. A., Smith A. P. Treatment of pulmonary infections caused by mycobacteria of the Mycobacterium avium-intracellulare complex. Thorax. 1981 May;36(5):326–329. doi: 10.1136/thx.36.5.326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Iseman M. D., Corpe R. F., O'Brien R. J., Rosenzwieg D. Y., Wolinsky E. Disease due to Mycobacterium avium-intracellulare. Chest. 1985 Feb;87(2 Suppl):139S–149S. doi: 10.1378/chest.87.2.139s. [DOI] [PubMed] [Google Scholar]
  54. Iseman M. D. Mycobacterium avium complex and the normal host: the other side of the coin. N Engl J Med. 1989 Sep 28;321(13):896–898. doi: 10.1056/NEJM198909283211310. [DOI] [PubMed] [Google Scholar]
  55. Isenberg H. D. Antimicrobial susceptibility testing: a critical evaluation. J Antimicrob Chemother. 1988 Jul;22 (Suppl A):73–86. doi: 10.1093/jac/22.supplement_a.73. [DOI] [PubMed] [Google Scholar]
  56. Jacobs W. R., Jr, Barletta R. G., Udani R., Chan J., Kalkut G., Sosne G., Kieser T., Sarkis G. J., Hatfull G. F., Bloom B. R. Rapid assessment of drug susceptibilities of Mycobacterium tuberculosis by means of luciferase reporter phages. Science. 1993 May 7;260(5109):819–822. doi: 10.1126/science.8484123. [DOI] [PubMed] [Google Scholar]
  57. Kemper C. A., Havlir D., Haghighat D., Dubé M., Bartok A. E., Sison J. P., Yao Y., Yangco B., Leedom J. M., Tilles J. G. The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. J Infect Dis. 1994 Jul;170(1):157–164. doi: 10.1093/infdis/170.1.157. [DOI] [PubMed] [Google Scholar]
  58. Kemper C. A., Meng T. C., Nussbaum J., Chiu J., Feigal D. F., Bartok A. E., Leedom J. M., Tilles J. G., Deresinski S. C., McCutchan J. A. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group. Ann Intern Med. 1992 Mar 15;116(6):466–472. doi: 10.7326/0003-4819-116-6-466. [DOI] [PubMed] [Google Scholar]
  59. Kennedy T. P., Weber D. J. Nontuberculous mycobacteria. An underappreciated cause of geriatric lung disease. Am J Respir Crit Care Med. 1994 Jun;149(6):1654–1658. doi: 10.1164/ajrccm.149.6.8004325. [DOI] [PubMed] [Google Scholar]
  60. Kiehn T. E., Edwards F. F., Brannon P., Tsang A. Y., Maio M., Gold J. W., Whimbey E., Wong B., McClatchy J. K., Armstrong D. Infections caused by Mycobacterium avium complex in immunocompromised patients: diagnosis by blood culture and fecal examination, antimicrobial susceptibility tests, and morphological and seroagglutination characteristics. J Clin Microbiol. 1985 Feb;21(2):168–173. doi: 10.1128/jcm.21.2.168-173.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Kuze F., Kurasawa T., Bando K., Lee Y., Maekawa N. In vitro and in vivo susceptibility of atypical mycobacteria to various drugs. Rev Infect Dis. 1981 Sep-Oct;3(5):885–897. doi: 10.1093/clinids/3.5.885. [DOI] [PubMed] [Google Scholar]
  62. LEWIS A. G., Jr, LASCHE E. M., ARMSTRONG A. L., DUNBAR F. P. A clinical study of the chronic lung disease due to nonphotochromogenic acid-fast bacilli. Ann Intern Med. 1960 Aug;53:273–285. doi: 10.7326/0003-4819-53-2-273. [DOI] [PubMed] [Google Scholar]
  63. Lee C. N., Heifets L. B. Determination of minimal inhibitory concentrations of antituberculosis drugs by radiometric and conventional methods. Am Rev Respir Dis. 1987 Aug;136(2):349–352. doi: 10.1164/ajrccm/136.2.349. [DOI] [PubMed] [Google Scholar]
  64. Lincoln E. M., Gilbert L. A. Disease in children due to mycobacteria other than Mycobacterium tuberculosis. Am Rev Respir Dis. 1972 May;105(5):683–714. doi: 10.1164/arrd.1972.105.5.683. [DOI] [PubMed] [Google Scholar]
  65. Lorian V., Sabath L. D. Effect of pH on the activity of erythromycin against 500 isolates of gram-negative bacilli. Appl Microbiol. 1970 Nov;20(5):754–756. doi: 10.1128/am.20.5.754-756.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Masur H. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. N Engl J Med. 1993 Sep 16;329(12):898–904. doi: 10.1056/NEJM199309163291228. [DOI] [PubMed] [Google Scholar]
  67. Masur H., Tuazon C., Gill V., Grimes G., Baird B., Fauci A. S., Lane H. C. Effect of combined clofazimine and ansamycin therapy on Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. J Infect Dis. 1987 Jan;155(1):127–129. doi: 10.1093/infdis/155.1.127. [DOI] [PubMed] [Google Scholar]
  68. Mor N., Heifets L. MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages. Antimicrob Agents Chemother. 1993 Jan;37(1):111–114. doi: 10.1128/aac.37.1.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Mor N., Simon B., Mezo N., Heifets L. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob Agents Chemother. 1995 Sep;39(9):2073–2077. doi: 10.1128/aac.39.9.2073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Mor N., Vanderkolk J., Heifets L. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob Agents Chemother. 1994 May;38(5):1161–1164. doi: 10.1128/aac.38.5.1161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Nightingale S. D., Byrd L. T., Southern P. M., Jockusch J. D., Cal S. X., Wynne B. A. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis. 1992 Jun;165(6):1082–1085. doi: 10.1093/infdis/165.6.1082. [DOI] [PubMed] [Google Scholar]
  72. O'Brien R. J., Geiter L. J., Snider D. E., Jr The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey. Am Rev Respir Dis. 1987 May;135(5):1007–1014. doi: 10.1164/arrd.1987.135.5.1007. [DOI] [PubMed] [Google Scholar]
  73. Parker B. C., Ford M. A., Gruft H., Falkinham J. O., 3rd Epidemiology of infection by nontuberculous mycobacteria. IV. Preferential aerosolization of Mycobacterium intracellulare from natural waters. Am Rev Respir Dis. 1983 Oct;128(4):652–656. doi: 10.1164/arrd.1983.128.4.652. [DOI] [PubMed] [Google Scholar]
  74. Perronne C., Gikas A., Truffot-Pernot C., Grosset J., Vilde J. L., Pocidalo J. J. Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. Antimicrob Agents Chemother. 1991 Jul;35(7):1356–1359. doi: 10.1128/aac.35.7.1356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Pransky S. M., Reisman B. K., Kearns D. B., Seid A. B., Collins D. L., Krous H. F. Cervicofacial mycobacterial adenitis in children: endemic to San Diego? Laryngoscope. 1990 Sep;100(9):920–925. doi: 10.1288/00005537-199009000-00002. [DOI] [PubMed] [Google Scholar]
  76. Prince D. S., Peterson D. D., Steiner R. M., Gottlieb J. E., Scott R., Israel H. L., Figueroa W. G., Fish J. E. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med. 1989 Sep 28;321(13):863–868. doi: 10.1056/NEJM198909283211304. [DOI] [PubMed] [Google Scholar]
  77. Reich J. M., Johnson R. E. Mycobacterium avium complex pulmonary disease. Incidence, presentation, and response to therapy in a community setting. Am Rev Respir Dis. 1991 Jun;143(6):1381–1385. doi: 10.1164/ajrccm/143.6.1381. [DOI] [PubMed] [Google Scholar]
  78. Ruf B., Schürmann D., Mauch H., Jautzke G., Fehrenbach F. J., Pohle H. D. Effectiveness of the macrolide clarithromycin in the treatment of Mycobacterium avium complex infection in HIV-infected patients. Infection. 1992 Sep-Oct;20(5):267–272. doi: 10.1007/BF01710792. [DOI] [PubMed] [Google Scholar]
  79. Seydel J. K., Schaper K. J., Rüsch-Gerdes S. Development of effective drug combinations for the inhibition of multiply resistant mycobacteria, especially of the Mycobacterium avium complex. Chemotherapy. 1992;38(3):159–168. doi: 10.1159/000238957. [DOI] [PubMed] [Google Scholar]
  80. Siddiqi S. H., Heifets L. B., Cynamon M. H., Hooper N. M., Laszlo A., Libonati J. P., Lindholm-Levy P. J., Pearson N. Rapid broth macrodilution method for determination of MICs for Mycobacterium avium isolates. J Clin Microbiol. 1993 Sep;31(9):2332–2338. doi: 10.1128/jcm.31.9.2332-2338.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Sison J. P., Yao Y., Kemper C. A., Hamilton J. R., Brummer E., Stevens D. A., Deresinski S. C. Treatment of Mycobacterium avium complex infection: do the results of in vitro susceptibility tests predict therapeutic outcome in humans? J Infect Dis. 1996 Mar;173(3):677–683. doi: 10.1093/infdis/173.3.677. [DOI] [PubMed] [Google Scholar]
  82. Spark R. P., Fried M. L., Bean C. K., Figueroa J. M., Crowe C. P., Jr, Campbell D. P. Nontuberculous mycobacterial adenitis of childhood. The ten-year experience at a community hospital. Am J Dis Child. 1988 Jan;142(1):106–108. doi: 10.1001/archpedi.1988.02150010116037. [DOI] [PubMed] [Google Scholar]
  83. Swensen S. J., Hartman T. E., Williams D. E. Computed tomographic diagnosis of Mycobacterium avium-intracellulare complex in patients with bronchiectasis. Chest. 1994 Jan;105(1):49–52. doi: 10.1378/chest.105.1.49. [DOI] [PubMed] [Google Scholar]
  84. Swenson J. M., Thornsberry C., Silcox V. A. Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution. Antimicrob Agents Chemother. 1982 Aug;22(2):186–192. doi: 10.1128/aac.22.2.186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Taha A. M., Davidson P. T., Bailey W. C. Surgical treatment of atypical mycobacterial lymphadenitis in children. Pediatr Infect Dis. 1985 Nov-Dec;4(6):664–667. doi: 10.1097/00006454-198511000-00013. [DOI] [PubMed] [Google Scholar]
  86. Telenti A., Imboden P., Marchesi F., Lowrie D., Cole S., Colston M. J., Matter L., Schopfer K., Bodmer T. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993 Mar 13;341(8846):647–650. doi: 10.1016/0140-6736(93)90417-f. [DOI] [PubMed] [Google Scholar]
  87. Truffot-Pernot C., Ji B., Grosset J. Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. Antimicrob Agents Chemother. 1991 Aug;35(8):1677–1678. doi: 10.1128/aac.35.8.1677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Tsukamura M. Evidence that antituberculosis drugs are really effective in the treatment of pulmonary infection caused by Mycobacterium avium complex. Am Rev Respir Dis. 1988 Jan;137(1):144–148. doi: 10.1164/ajrccm/137.1.144. [DOI] [PubMed] [Google Scholar]
  89. Tsukamura M., Kita N., Shimoide H., Arakawa H., Kuze A. Studies on the epidemiology of nontuberculous mycobacteriosis in Japan. Am Rev Respir Dis. 1988 Jun;137(6):1280–1284. doi: 10.1164/ajrccm/137.6.1280. [DOI] [PubMed] [Google Scholar]
  90. Tsukamura M., Shimoide H., Kita N., Kawakami K., Ito T., Nakajima N., Kondo H., Yamamoto Y., Matsuda N., Tamura M. Epidemiologic studies of lung disease due to mycobacteria other than Mycobacterium tuberculosis in Japan. Rev Infect Dis. 1981 Sep-Oct;3(5):997–1007. doi: 10.1093/clinids/3.5.997. [DOI] [PubMed] [Google Scholar]
  91. Wallace R. J., Jr, Brown B. A., Griffith D. E., Girard W. M., Murphy D. T., Onyi G. O., Steingrube V. A., Mazurek G. H. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med. 1994 May;149(5):1335–1341. doi: 10.1164/ajrccm.149.5.8173775. [DOI] [PubMed] [Google Scholar]
  92. Wallace R. J., Jr, Nash D. R., Steele L. C., Steingrube V. Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth. J Clin Microbiol. 1986 Dec;24(6):976–981. doi: 10.1128/jcm.24.6.976-981.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Wendt S. L., George K. L., Parker B. C., Gruft H., Falkinham J. O., 3rd Epidemiology of infection by nontuberculous Mycobacteria. III. Isolation of potentially pathogenic mycobacteria from aerosols. Am Rev Respir Dis. 1980 Aug;122(2):259–263. doi: 10.1164/arrd.1980.122.2.259. [DOI] [PubMed] [Google Scholar]
  94. Williams D. L., Waguespack C., Eisenach K., Crawford J. T., Portaels F., Salfinger M., Nolan C. M., Abe C., Sticht-Groh V., Gillis T. P. Characterization of rifampin-resistance in pathogenic mycobacteria. Antimicrob Agents Chemother. 1994 Oct;38(10):2380–2386. doi: 10.1128/aac.38.10.2380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis. 1979 Jan;119(1):107–159. doi: 10.1164/arrd.1979.119.1.107. [DOI] [PubMed] [Google Scholar]
  96. Wong B., Edwards F. F., Kiehn T. E., Whimbey E., Donnelly H., Bernard E. M., Gold J. W., Armstrong D. Continuous high-grade mycobacterium avium-intracellulare bacteremia in patients with the acquired immune deficiency syndrome. Am J Med. 1985 Jan;78(1):35–40. doi: 10.1016/0002-9343(85)90458-9. [DOI] [PubMed] [Google Scholar]
  97. Woods G. L., Washington J. A., 2nd Mycobacteria other than Mycobacterium tuberculosis: review of microbiologic and clinical aspects. Rev Infect Dis. 1987 Mar-Apr;9(2):275–294. doi: 10.1093/clinids/9.2.275. [DOI] [PubMed] [Google Scholar]
  98. Yajko D. M., Nassos P. S., Hadley W. K. Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome. Antimicrob Agents Chemother. 1987 Oct;31(10):1579–1584. doi: 10.1128/aac.31.10.1579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Yajko D. M., Nassos P. S., Sanders C. A., Gonzalez P. C., Hadley W. K. Comparison of the intracellular activities of clarithromycin and erythromycin against Mycobacterium avium complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals. Antimicrob Agents Chemother. 1992 May;36(5):1163–1165. doi: 10.1128/aac.36.5.1163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Yeager H., Jr, Raleigh J. W. Pulmonary disease due to Mycobacterium intracellulare. Am Rev Respir Dis. 1973 Sep;108(3):547–552. doi: 10.1164/arrd.1973.108.3.547. [DOI] [PubMed] [Google Scholar]
  101. Young L. S., Inderlied C. B., Berlin O. G., Gottlieb M. S. Mycobacterial infections in AIDS patients, with an emphasis on the Mycobacterium avium complex. Rev Infect Dis. 1986 Nov-Dec;8(6):1024–1033. doi: 10.1093/clinids/8.6.1024. [DOI] [PubMed] [Google Scholar]
  102. Young L. S., Wiviott L., Wu M., Kolonoski P., Bolan R., Inderlied C. B. Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS. Lancet. 1991 Nov 2;338(8775):1107–1109. doi: 10.1016/0140-6736(91)91965-w. [DOI] [PubMed] [Google Scholar]
  103. Zakowski P., Fligiel S., Berlin G. W., Johnson L., Jr Disseminated Mycobacterium avium-intracellulare infection in homosexual men dying of acquired immunodeficiency. JAMA. 1982 Dec 10;248(22):2980–2982. doi: 10.1001/jama.1982.03330220024029. [DOI] [PubMed] [Google Scholar]
  104. de Lalla F., Maserati R., Scarpellini P., Marone P., Nicolin R., Caccamo F., Rigoli R. Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. Antimicrob Agents Chemother. 1992 Jul;36(7):1567–1569. doi: 10.1128/aac.36.7.1567. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES